Abivax

60 articles with Abivax

• 

  BioSpace Global Roundup, Aug. 22

  8/22/2019

  Companies from across the globe provide updates on their business and pipelines.

• Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464

  8/1/2019

  Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today that the first patient was dosed in study ABX464-301, a phase 2a clinical trial of ABX464 to treat patients with moderate to severe active rheumatoid arthritis (RA).

• 

  BioSpace's Global Biopharma Roundup: May 2

  5/2/2019

  Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
• 

  BioSpace's Global Biopharma Roundup: Jan. 31

  1/31/2019

  It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup...

• Abivax’s Phase 2a Ulcerative Colitis Clinical Trial Data Selected for Oral Plenary Presentation at 14th Congress of European Crohn’s and Colitis Organisation

  12/20/2018

  Favorable safety and statistically significant efficacy of oral ABX464 demonstrated in a completed randomized, double-blind, placebo-controlled induction trial based on clinical and endoscopic endpoints

• Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients

  12/6/2018

  Favorable safety and statistically significant efficacy demonstrated in a completed randomized, double-blind, placebo-controlled induction clinical trial based on clinical and endoscopic endpoints

• 

  Abivax Bolstered by Positive Mid-Stage Results from Ulcerative Colitis Treatment

  9/4/2018

  Shares of Paris-based Abivax have shot up more than 8 percent this morning after the company posted positive mid-stage results for its ulcerative colitis treatment, ABX464.
• 

  Biotech Leadership Transformations for July 2

  7/2/2018

  With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.

• ABIVAX Presents New Data on ABX464 Mechanism of Action at 16th European Meeting on HIV & Hepatitis

  5/31/2018

  ABIVAX (Euronext Paris: FR0012333284 - ABVX), today unveiled new data characterizing the mechanism of action of its lead Phase 2 clinical candidate ABX464.

• ABIVAX 2017 Full-Year Results and Progress Report

  3/16/2018

  Reinforced cash position finances operations through key clinical milestones to mid-2019, phase IIb clinical programs for ABX464 in HIV and IBD patients expected to be initiated around end of 2018.

• ABIVAX to Initiate Long-Term Extension Study of ABX464 in Patients With Ulcerative Colitis

  1/4/2018

  The new study will recruit patients from the ongoing ulcerative colitis proof-of-concept study who are responding to treatment with ABX464 into the 12-month open label follow-up study.

• ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018

  12/21/2017

  Abivax announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

• ABIVAX to Participate in 'Corporate Access' Event in San Francisco, January 8 - 10, 2018

  12/21/2017

  Abivax today announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

• ABIVAX to Present in Plenary Session at the 8th International Conference on HIV Persistence During Therapy

  12/7/2017

  The conference will take place December 12-15 at the Marriott Biscayne Bay Resort in Miami, FL.

• Abivax Presents Novel Data On The Efficacy Of Its Immune Enhancer ABX196 In Animal Model Of Liver Cancer At The World Vaccine Congress

  10/13/2017

• Abivax Expands Scientific Advisory Board With Appointment Of Renowned Virologist And Former President Of Pasteur Institute, Prof. Christian Bréchot

  10/9/2017

• Abivax Receives French Regulatory Approval To Begin Clinical Trial Of ABX464 In Ulcerative Colitis

  9/22/2017

• Abivax First-Half 2017 Financial Results And Update

  9/22/2017

• Abivax: First Patient Dosed In Three-Month Cohort Of Phase 2a Study Of Oral ABX464 In HIV-Suppressed Patients

  9/18/2017

• Abivax Presents Full ABX464 Positive Phase IIA Clinical HIV Data At The HIV Cure And Reservoir Symposium

  9/13/2017